Skip to main content
. 2011 Sep 9;4:35. doi: 10.1186/1756-8722-4-35

Table 7.

Treatment recommendations:

First line treatment Second and third line treatments
Patients eligible to cisplatin Unfit patients Cisplatin sensitive disease Cisplatin refractory disease

MVAC, HD-MVAC, GC, and DD-GC GCa and MCAVI Cisplatin based doublet not used in first line Vinflunine, Paclitaxel-Gemcitabine, and all actives drugs not used